IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy (Harmony1)
This study has been completed.
Sponsor:
Bioprojet
Information provided by (Responsible Party):
Bioprojet
ClinicalTrials.gov Identifier:
NCT01067222
First received: February 9, 2010
Last updated: June 8, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate the efficacy and safety of BF2.649 administered by individual titration in narcoleptic patients with excessive daytime sleepiness (EDS)
| Condition | Intervention | Phase |
|---|---|---|
| Narcolepsy Excessive Daytime Sleepiness Cataplexy Sleep Disorders | Drug: BF2.649 Drug: Modafinil Drug: Placebo | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy |
Resource links provided by NLM:
Further study details as provided by Bioprojet:
Primary Outcome Measures:
- Epworth Sleepiness Scale (ESS) [ Time Frame: between baseline and at the end of 8 week DB phase ]
Secondary Outcome Measures:
- Sleep Diary: Number and duration of diurnal sleep and sleepiness episodes, number of cataplexy attacks [ Time Frame: 14 days before randomization and 7 days before each visit ]
- Maintenance of Wakefulness Test (MWT), Test of Sustained Attention to Response Task (SART). [ Time Frame: at inclusion and after 8-week treatment ]
| Enrollment: | 110 |
| Study Start Date: | May 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: BF2.649 |
Drug: BF2.649
BF2.649 oral capsules at 10 or 20 or 40 mg per day
Other Name: Pitolisant
|
| Active Comparator: Modafinil |
Drug: Modafinil
Modafinil oral capsules at 100 or 200 or 400 mg per day
Other Name: Modiodal
|
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo oral capsules, 4 capsules per day
|
Detailed Description:
BF 2.649, a new experimental drug, significantly decreases, in patient with narcolepsy, the excessive daytime sleepiness (EDS) evaluated by Epworth Sleepiness Scale (ESS), according the results of two previous clinical studies.
The objective of this study is to determine the efficacy and safety of BF2.649 administered by escalating dose (10, 20 or 40 mg/d) in narcoleptic patients with excessive daytime sleepiness versus placebo and Modafinil as assessed by both of objective and subjective measures including ESS, MWT, patients sleep diary.
60 patients with narcolepsy with or without cataplexy will be included.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- diagnosis of narcolepsy with or without cataplexy
- patients need to free of or discontinue psychostimulant medications for at least 14 days,
- patients with severe cataplexy are permitted to remain on their anticataplectic medications at stable doses
- patients must have adequate support to comply with the entire study requirements
Exclusion Criteria:
- Other conditions than Narcolepsy that can be considered as the primary causes of excessive daytime sleepiness
- Patients who are unable or unwilling to temporarily discontinue any no-authorized drugs or substances
- Psychiatric and neurological disorders such as psychosis or dementia, bipolar illness, severe anxiety, clinical depression, history of seizure disorder or other problem that in the investigator's opinion would preclude the patient's participation
- Current or recent history of a substance abuse or dependence disorder including alcohol abuse
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01067222
Please refer to this study by its ClinicalTrials.gov identifier: NCT01067222
Locations
| Switzerland | |
| Neurocenter (EOC) of Southern Switzerland | |
| Lugano, Switzerland, 6903 | |
Sponsors and Collaborators
Bioprojet
Investigators
| Principal Investigator: | Claudio Bassetti | Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bioprojet |
| ClinicalTrials.gov Identifier: | NCT01067222 History of Changes |
| Other Study ID Numbers: |
P07-03 / BF2.649 2008-007866-46 ( EudraCT Number ) |
| Study First Received: | February 9, 2010 |
| Last Updated: | June 8, 2012 |
Keywords provided by Bioprojet:
|
Narcolepsy Excessive daytime Sleepiness Cataplexy Sleep Disorders |
Sleep attacks Orphan Drug Pitolisant |
Additional relevant MeSH terms:
|
Sleep Wake Disorders Parasomnias Narcolepsy Cataplexy Nervous System Diseases Neurologic Manifestations Signs and Symptoms Mental Disorders Disorders of Excessive Somnolence Sleep Disorders, Intrinsic |
Dyssomnias Modafinil Armodafinil Wakefulness-Promoting Agents Central Nervous System Stimulants Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on August 18, 2017